


TFW



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re application of:** Swain et al.

**Application No.** 10/647,071

**Filed:** August 22, 2003

**Confirmation No.** 9609

**For:** HAPTEN-CARRIER CONJUGATES FOR  
USE IN DRUG-ABUSE THERAPY AND  
METHODS FOR PREPARATION OF  
SAME

**Examiner:** Unassigned

**Art Unit:** 1641

**Attorney Reference No.** 5673-66690-01

COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450

**CERTIFICATE OF MAILING**

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent  
for Applicant(s)

Date Mailed October 25, 2005

**INFORMATION DISCLOSURE STATEMENT**  
**FOR CONTINUING APPLICATIONS**

Listed on the accompanying form PTO-1449 are several English-language and/or non-English-language documents. Applicants respectfully request that such documents be listed as references cited on the issued patent.

The present application relies upon U.S. Patent Application No. 10/115,580 filed April 1, 2002, which is a continuation of U.S. Patent Application No. 09/882,803 filed June 14, 2001, which is a continuation of U.S. Patent Application No. 09/257,821, filed February 25, 1999, which is a continuation of U.S. Patent Application No. 08/720,487, filed September 30, 1996, which is a continuation-in-part of U.S. Patent Application No. 08/563,673, filed November 28, 1995, which is a continuation-in-part of U.S. Patent Application No. 08/414,971, filed March 31, 1995, for an earlier filing date under 35 U.S.C. § 120. Furthermore, documents listed on the accompanying form PTO-1449 were disclosed to or cited by the Patent Office in the earlier U.S. applications.

Copies of United States patents and United States published patent applications do not have to be provided to the Patent Office (37 C.F.R. 1.98(a)(2)(ii)). Copies of unpublished U.S.

applications do not have to be provided, as long as the application is available on PAIR, as this requirement of 37 C.F.R. § 1.98(a)(2)(iii) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on October 19, 2004 (1287 OG 163). Applicants will provide copies of such patents or applications upon request.

Copies of the documents listed on the accompanying form PTO-1449 that were cited by applicants or cited by the Patent Office in an earlier application need not be sent to the Patent Office pursuant to 37 C.F.R. § 1.98. However, applicants will furnish the Patent Office with such copies upon request.

Please charge any additional fees that may be required in connection with filing this Information Disclosure Statement, or credit any overpayment, to Deposit Account No. 02-4550. A duplicate copy of this sheet is enclosed.


The filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Please return the enclosed postcard to confirm that the items listed above have been received.


Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 595-5300  
Facsimile: (503) 595-5301

By   
Susan Alpert Siegel, Ph.D.  
Registration No. 43,121

cc: Docketing



# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	5673-66690-01
Application Number	10/647,071
Filing Date	August 22, 2003
First Named Inventor	Philip A. Swain
Art Unit	1641
Examiner Name	To be assigned

## U.S. PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		3,888,886	10 June 1975	Young et al.
		4,045,420	30 Aug 1977	Soffer et al.
		4,123,431	31 Oct 1978	Soffer et al.
		4,129,237	12 Dec 1978	Grinder
		4,197,237	08 Apr 1980	Leute et al.
		4,235,864	25 Nov 1980	Kaul et al.
		4,375,414	01 Mar 1983	Strahilevitz
		4,376,825	15 Mar 1983	Rubenstein et al.
		4,620,977	04 Nov 1986	Strahilevitz
		4,666,837	19 May 1987	Harford et al.
		4,791,067	13 Dec 1988	Sheiman et al.
		4,813,924	21 Mar 1989	Strahilevitz
		4,834,973	30 May 1989	Strahilevitz
		5,019,384	28 May 1991	Gefter et al.
		5,037,645	06 Aug 1991	Strahilevitz
		5,229,490	20 July 1993	Tam

EXAMINER  
SIGNATURE:

DATE  
CONSIDERED:

\* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

Attorney Docket Number	5673-66690-01
Application Number	10/647,071
Filing Date	August 22, 2003
First Named Inventor	Philip A. Swain
Art Unit	1641
Examiner Name	To be assigned

**U.S. PATENT DOCUMENTS**

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		5,256,409	26 Oct 1993	Blincko
		5,268,276	07 Dec 1993	Holmgren et al.
		5,283,066	01 Feb 1994	Liu et al.
		5,876,727	02 Mar 1999	Swain et al
		6,210,677	03 Apr 2001	Bohannon

**FOREIGN PATENT DOCUMENTS**

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		Europe	EP 0 311 383	Apr 1989	UBE INDUSTRIES
		Europe	EP 0 363 041	Apr 1990	UBE INDUSTRIES
		Europe	EP 0 613 899 A2	Sep 1994	MATSUSHITA ELECTRIC IND CO LTD
		Germany	DE2202441	Mar1973	HOFFMANN LA ROCHE
		Germany	DE2548196	Apr 1977	HOFFMANN LA ROCHE
		Soviet Union	792869	Mar 1982	NII BIOLOG ISPYTANIYAM KHIM SO

EXAMINER  
SIGNATURE:

DATE  
CONSIDERED:

\* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Attorney Docket Number	5673-66690-01
	Application Number	10/647,071
	Filing Date	August 22, 2003
	First Named Inventor	Philip A. Swain
	Art Unit	1641
	Examiner Name	To be assigned

### FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		Soviet Union	1123704A	Nov 1984	NII BIOLOG ISPYTANIYAM KHM SO
		PCT	WO 92/03163	Mar 1992	CERNY ERICH H
		PCT	WO 93/12111	June 1993	BIOSITE DIAGNOSTICS INC
		PCT	WO 93/23076	Nov 1993	UNIV JOHNS HOPKINS
		PCT	WO 94/27576	Dec 1994	DANBIOSYST; ILLUM LISBETH
		PCT	WO 95/07922	Mar 1995	SMITHKLINE BEECHAM CORP; LEE JOHN C
		PCT	WO 95/27786	Oct 1995	IMMULOGIC PHARMA CORP
		PCT	WO 96/30049	Mar 1996	IMMULOGIC PHARMA CORP

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS
		Ambre et al., "A Kinetic Model of Benzoylcegonine Disposition after Cocaine Administration in Humans," <i>Journal of Analytical Toxicology</i> Vol. 15, pp. 17-20, January/February 1991
		Bagasra et al., "A Potential Vaccine for Cocaine Abuse Prophylaxis," <i>Immunopharmacology</i> 23:173-179, 1992
		Beckstead et al., "Fourier Transform-Infrared (FT-IR) Characterization of Ethyl Acetate Complex of O <sup>6</sup> -Acetylmorphine," <i>J. Forensic Sci.</i> , Vol. 33(1):223-229, January 1988
		Beckstead et al., "Fourier Transform-Infrared (FT-IR) Characterization of Ethyl Acetate Complex of O <sup>6</sup> -Acetylmorphine," <i>Chem. Abs.</i> 108:144839, 1998
		Berkower, "Synthetic T Cell Epitope Peptides Used for Desensitization," <i>Paul-Ehrlich-Institute</i> 1009-1014, 1994
		Berkowitz, "Evidence for Active Immunity to Morphine in Mice," <i>Science</i> 178:1290-1292, 1972

EXAMINER SIGNATURE:	DATE CONSIDERED:
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Attorney Docket Number	5673-66690-01
		Application Number	10/647,071
		Filing Date	August 22, 2003
		First Named Inventor	Philip A. Swain
		Art Unit	1641
		Examiner Name	To be assigned
		Berkowitz, "Influence of Active and Passive Immunity on the Disposition of Dihydromorphine-H <sup>3</sup> ," <i>Life Sciences</i> 15:1017-1028, 1975	
		Bonese et al., "Changes in Heroin Self-Administration by a Rhesus Monkey after Morphine Immunisation," <i>Nature</i> 252:708-710, December 1974	
		Carroll et al., "Effects of Buprenorphine on Self-Administration of Cocaine and a Nondrug Reinforcer in Rats," <i>Psychopharmacology</i> 106:439-446, 1992	
		Carroll et al., "Chemical Approaches to the treatment of Cocaine Abuse," <i>Pharm. News</i> 1:11-17, 1994	
		Castro et al., "Nicotine Antibody Production: Comparison of Two Nicotine Conjugates in Different Animal Species," <i>Biochemical and Biophysical Research Communications</i> Vol. 67, No. 2, pp. 583-589, 1975	
		Castro et al., "Nicotine Antibodies: Comparison of Ligand Specificities of Antibodies Produced against Two Nicotine Conjugates," <i>Eur. J. Biochem.</i> 104:331-340, 1980	
		Castro et al., "Characterization of Antibodies to Nicotine," <i>Biochemical Archives</i> 1:173-178, 1985	
		Castro et al., "Nicotine Enzyme Immunoassay," <i>Research Communications in Chemical Pathology and Pharmacology</i> 51:393-404, March 1986	
		Castro et al., "Nicotine Antibodies: Comparison of Ligand Specificities of Antibodies Produced against Two Nicotine Conjugates," <i>Chem. Abs.</i> 92:209666, 1998	
		Castro et al., "Characterization of Antibodies to Nicotine", <i>Chem. Abs.</i> 103:213004, 1998	
		Chuong et al., "Study on Anti-Aspirin Antibodies Obtained in Rabbits after Immunization with Various Aspirin-Protein Conjugates," <i>Annales Pharmaceutiques Françaises</i> 35(7-8):257-264, 1977 (Translation)	
		Colburn, "Specific Antibodies and Fab Fragments to Alter the Pharmacokinetics and Reverse the Pharmacologic/Toxicologic Effects of Drugs," <i>Drug Method Rev.</i> 11:223-262, 1980	
		Curreru et al., "Suppression of Cocaine-Induced Locomotion by Immunization with a Novel Cocaine Conjugate," <i>Society of Neuroscience</i> 754.4, 1993 (Abstract)	
		Decato et al., "Immunologic Studies on Drug Addiction: III. Antibodies Reactive with Cocaine Metabolites and Their Use for Drug Detection," <i>Journal of Immunological Methods</i> 18:201-213, 1977	
		Gallacher, "A Potential Vaccine for Cocaine Abuse Prophylaxis?" <i>Immunopharm.</i> 27:79-81, 1994	

EXAMINER  
SIGNATURE:DATE  
CONSIDERED:

\* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Attorney Docket Number	5673-66690-01
		Application Number	10/647,071
		Filing Date	August 22, 2003
		First Named Inventor	Philip A. Swain
		Art Unit	1641
		Examiner Name	To be assigned
		Harless et al., "Abstract: Active Immunization Prevents Analgesic and Reinforcing Effects of Cocaine," <i>Twenty-fourth Annual Western Psychology Conference</i> , April 1995	
		Herndon et al., "Attenuation of Morphine Analgesia by Serum from Morphine-Treated Rabbits," <i>Life Sciences</i> 17:151-158, 1975	
		Holmgren et al., "Strategies for the Induction of Immune Responses at Mucosal Surfaces Making Use of Cholera Toxin B Subunit as Immunogen, Carrier, and Adjuvant," <i>Am. J. Trop. Med. Hyg.</i> pp. 42-54, 1994	
		Inaba, "Cocaine: Pharmacokinetics and Biotransformation in Man," <i>SFBS Symposium on Frontiers in Cocaine Research</i> , Quebec, Canada, pp. 1154-1157, June 15, 1988	
		Inaba, "Cocaine: pharmacokinetics and biotransformation in man," <i>Can. J. Physiol. Pharmacol.</i> 67:1154-1157, 1989	
		Jatlow, "Cocaine: Analysis, Pharmacokinetics, and Metabolic Disposition," <i>The Yale Journal of Biology and Medicine</i> 61:105-113, 1988	
		Jindal et al., "Mass spectrometric studies of cocaine disposition in animals and humans using stable isotope-labeled analogues," <i>J. Pharm. Sciences</i> 78(12):1009-10014, 1989	
		Jones-Witters et al., <i>Drugs and Society – A Biological Perspective</i> , Wadsworth Health Services Division, Wadsworth, Inc., Belmont, CA, 94002, pp. 142-147, 1983	
		Kantak et al., "Acute and Multiple Injection Effects of Magnesium on Responding Maintained by Cocaine, Extinction from Cocaine, Glucose + Saccharin, and Food," <i>Pharm. Biochem. and Behavior</i> , 41:415-423, 1992	
		Killian et al., "Effects of Passive Immunization Against Morphine on Heroin Self-Administration," <i>Pharmacol. Biochem. Behavior</i> 9:347-352, 1978	
		Kovalev et al., "Diminishment of the Effects of Morphine in Rats Immunized with a Morphine-Protein Conjugated Antigen," <i>Khim. Pharm. (USSR)</i> pp. 615-618, 1979	
		Kovalev et al., "Effect of the Active Immunization of Rats Using a Conjugate of Morphine with Bovine Serum Albumin (M-BSA) on the Self-Consumption of Morphine," <i>Khim. Pharm. (USSR)</i> pp. 200-204, 1980	
		Landry et al., "Antibody-Catalyzed Degradation of Cocaine," <i>Science</i> 259:1899-1901, March 26, 1993	
		Lomax et al., "Immunological Blockade of the Analgesic Effect of Morphine in the Rat," <i>Proc. West. Pharmacol. Soc.</i> 16:252-256, 1973	
		Manganaro, "Oral Immunization: Turning Fantasy into Reality," <i>Int. Arch. Immunol.</i> 103:223-233, 1994	

EXAMINER SIGNATURE:	DATE CONSIDERED:
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Attorney Docket Number	5673-66690-01
		Application Number	10/647,071
		Filing Date	August 22, 2003
		First Named Inventor	Philip A. Swain
		Art Unit	1641
		Examiner Name	To be assigned
		Matsushita et al., "Conjugate of Bovine Serum Albumin with Nicotine," <i>Biochemical and Biophysical Research Communications</i> Vol. 57, No. 4, pp 1006-1010, 1974	
		McKenzie et al., "Cholera Toxin B Subunit as a Carrier Protein to Stimulate a Mucosal Immune Response," <i>The Journal of Immunology</i> 133(4):1818-1824, October 1984	
		Miller et al., "Attenuation of Morphine Analgesia by Immunological Manipulations," <i>Proc. West Pharmacol. Soc.</i> 17:69-72, 1974	
		Pentel et al., "Redistribution of Tricyclic Antidepressants in Rats Using a Drug-Specific Monoclonal Antibody: Dose-Response Relationship," <i>Drug Meth. &amp; Disp.</i> 19:24-28, 1991	
		Schmidt et al., "Immunological Protection against Digoxin Toxicity," <i>The Journal of Clinical Investigation</i> 50:866-871, 1971	
		Slos, "Recombinant Cholera Toxin B Subunit in <i>Escherichia coli</i> : High-Level Secretion, Purification, and Characterization," <i>Protein Expression and Purification</i> 5:518-526, 1994	
		Spector et al., "Morphine: Radioimmunoassay," <i>Science</i> 168:1347-1348, 1970	
		Spector, "Quantitative Determination of Morphine in Serum by Radioimmunoassay," <i>The Journal of Pharmacology and Experimental Therapeutics</i> 178:253-258, 1971	
		Spector et al., "Antibodies to Morphine, Barbiturates, and Serotonin," <i>Pharmacological Reviews</i> Vol. 25, No. 2 pp. 281-291, 1973	
		Spector, "Antibodies as Pharmacological Agents," <i>Biochemical Pharmacology</i> 25:2427-2428, 1976	
		Stok et al., "Conversion of Orally Induced Suppression of the Mucosal Immune Response to Ovalbumin into Stimulation by Conjugating Ovalbumin to Cholera Toxin or its B Subunit," <i>Vaccine</i> Vol. 12, No. 6, pp 521-526, 1994	
		Van Vunakis et al., "Specificities of antibodies to morphine," <i>The Journal of Pharmacology and Experimental Therapeutics</i> 180:514-521, 1972	
		Wainer et al., "Morphine-3-Succinyl-Bovine Serum Albumin: An Immunogenic Hapten-Protein Conjugate," <i>Science</i> 176:1143-1145, 1972	
		Wainer et al., "The Structure of Morphine Monohemisuccinate," <i>Science</i> 178:647-648, November 10, 1972	
		Wainer et al., "In Vitro Morphine Antagonism by Antibodies," <i>Nature</i> 241:537-538, February 23, 1973	
		Wainer et al., "A Measurement of the Specificities of Antibodies to Morphine-6-Succinyl-BSA by Competitive Inhibition of <sup>14</sup> C-Morphine Binding," <i>The Journal of Immunology</i> Vol. 110, No. 3, pp 667-673, March 1973	

EXAMINER SIGNATURE:	DATE CONSIDERED:
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Attorney Docket Number	5673-66690-01
		Application Number	10/647,071
		Filing Date	August 22, 2003
		First Named Inventor	Philip A. Swain
		Art Unit	1641
		Examiner Name	To be assigned
		Witkin, "Pharmacotherapy of Cocaine Abuse: Preclinical Development," <i>Neuroscience and Biobehavioral Reviews</i> , Vol. 18, No. 1, pp 121-142, 1994	
		Wu et al., "Comparison of Systemic and Mucosal Priming for Mucosal Immune Responses to a Bacterial Protein Antigen Given with or Coupled to Cholera Toxin (CT) B Subunit, and Effects of Pre-Existing Anti-CT Immunity," <i>Vaccine</i> Vol. 12, No. 3, pp. 215-222, 1994	
		Zimmerman et al., "Immunological Suppression of Morphine Induced Analgesia and Pituitary-Adrenal Activation in the Rat and Respiratory Depression in the Rabbit," <i>Proc. West. Pharmacol. Soc.</i> Vol. 19, pp. 260-265, 1976	

EXAMINER SIGNATURE:	DATE CONSIDERED:
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	